Decline In Civil Discourse Harms US FDA's Operations, Woodcock Says
Executive Summary
'Polarization of opinions has always been a problem for us and has only been heightened,' CDER chief tells DIA.
You may also be interested in...
Lower Drug Costs Might End Perception US FDA Approval Standards Are Lower
CDER Director Woodcock says pricing and approval issues are becoming "conflated" but it is hard to change people's minds when they are "determinedly angry about something."
Sponsor-FDA Communications In IND Phase Will Get Outside Review
US FDA seeks White House approval for to contract for interviews with 100 to 150 active commercial IND holders.
Sarepta Should Gain Clean Slate With CBER Review of DMD Gene Therapy
Sarepta will face a US FDA staff with which it does not have a controversial history, the Center for Biologics Evaluation and Research, likely avoiding the reviewers that evaluated its Duchenne muscular dystrophy treatment Exondys 51.